Tirzepatide (Mounjaro / Zepbound) and Libido: Does It Raise or Lower Sex Drive?

Does tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight loss — raise or lower your sex drive? The honest answer is that no randomized trial has ever measured libido as an endpoint for tirzepatide, so anyone who tells you it definitely does one thing or the other is overstating the evidence. What the data does support is an indirect story that runs through weight: tirzepatide produces the largest non-surgical weight loss yet recorded (−20.9% at 72 weeks in SURMOUNT-1^[1]), and meaningful weight loss in people with obesity reliably improves the things libido depends on — testosterone in men, body image and mood in both sexes, and erectile and female sexual function. But the same drug can also blunt sex drive in the early weeks through nausea, fatigue, and the low-calorie catabolic state, and in some women it can shift libido by normalizing androgens. This article covers both directions, men and women, and the central question: is it the drug, or is it the rapid weight loss? For the general picture across all GLP-1 drugs see our GLP-1 libido and sex-drive hub; for women specifically, see the tirzepatide and sex drive in women deep dive.

The honest summary

• No tirzepatide RCT has measured libido. The SURMOUNT-1^[1] and SURMOUNT-2^[2] obesity trials collected weight, glycemic, and general quality-of-life data, but neither used a validated sexual-function instrument (IIEF, FSFI) as a primary or pre-specified secondary endpoint. Everything below is indirect inference, clearly labeled as such.
• The dominant effect over months is UP, via weight loss. Tirzepatide produces roughly −15% to −21% total body weight^[1][2] — comparable to or larger than the lifestyle intervention that restored erectile function in about a third of obese men in the landmark Esposito 2004 JAMA trial^[4]. The weight-loss-to-sexual-function chain is well established in both sexes.
• In men, weight loss tends to raise testosterone. Obesity lowers testosterone through adipose-tissue aromatase and suppressed GnRH signaling (Fui 2014^[8]); sustained weight loss reverses much of that (EMAS, Camacho 2013^[7]; Grossmann 2020^[9]), and a 2025 study found semaglutide improved markers in obese men with functional hypogonadism^[10]. Higher testosterone supports libido and erectile function.
• In women, the picture is more mixed. Obesity is linked to lower female sexual function (Princeton III, Miner 2012^[12]), and weight loss — including after bariatric surgery^[13] — tends to improve it. But in women with PCOS, GLP-1 receptor agonists lower elevated androgens^[14], which improves metabolic and reproductive health and may shift libido either way.
• The early weeks can lower sex drive. Nausea, fatigue, and the steep initial calorie deficit are the most common short-term reasons libido dips on tirzepatide. These usually ease as the dose is titrated and the body adapts. This is a tolerability effect, not a permanent drug effect.
• The GIP component is not shown to change libido independently. Tirzepatide is a dual GIP and GLP-1 receptor agonist. There is no published evidence that the GIP arm of its action has any direct, weight-independent effect on sex drive in either sex.
• It is mostly the weight loss, not a direct genital or brain effect. The most parsimonious read of the evidence is that tirzepatide changes libido the way any large, sustained weight loss does — through hormones, body composition, mood, and self-image — not through a dedicated receptor effect on desire.
• Persistent low libido deserves a workup. If sex drive stays low after the early adjustment period, the right move is a clinical evaluation — morning testosterone in men, thyroid and iron studies, a medication and mood review — not an assumption that the drug is solely to blame.

Why no trial answers this directly

Libido is hard to measure and is rarely a registration endpoint, so the pivotal tirzepatide trials simply did not capture it. SURMOUNT-1 (Jastreboff 2022 NEJM^[1]) randomized adults with obesity to tirzepatide or placebo and reported −20.9% body weight at the 15 mg dose over 72 weeks. SURMOUNT-2 (Garvey 2023 Lancet^[2]) studied adults with obesity and type 2 diabetes and reported weight loss in the −12% to −15% range. Both collected general quality-of-life and physical-function measures, but neither administered the International Index of Erectile Function (IIEF) or the Female Sexual Function Index (FSFI). The same gap exists across the whole GLP-1 class — even the much larger STEP semaglutide program (STEP-1, −14.9%^[3]) did not pre-specify a sexual-function endpoint.

That means every claim about tirzepatide and libido is, today, an inference from two solid bodies of evidence: (1) how much weight the drug removes, and (2) what weight loss of that magnitude does to sexual function in obese men and women. The chain is reasonable, but it is a chain — not a head-to-head measurement.

Why libido can go UP on tirzepatide

For most people with obesity, the medium-term direction is upward, and there are four converging reasons.

1. Reversal of obesity-associated low testosterone (men). Adipose tissue expresses aromatase, which converts testosterone to estradiol, and obesity suppresses hypothalamic GnRH pulsing — so obese men run measurably lower testosterone than lean peers (Fui 2014^[8]; Grossmann 2020^[9]). The EMAS longitudinal cohort (Camacho 2013^[7]) showed that large, sustained weight loss blunts or reverses the age-related testosterone decline, with mean total-testosterone gains on the order of 60–90 ng/dL in men who lost substantial weight. A 2025 study even found semaglutide improved sperm morphology in obese men with functional hypogonadism^[10]. Higher testosterone is one of the most direct drivers of male libido.
2. Better erectile and female sexual function. Obesity drives the endothelial dysfunction behind vascular erectile dysfunction, and the Esposito 2004 JAMA RCT^[4] showed intensive lifestyle weight loss restored erectile function in about 31% of obese men with ED. In women, obesity and cardiometabolic risk track with reduced sexual function (Princeton III, Miner 2012^[12]; Giugliano 2010^[11]), and that improves as weight comes off. Function and desire reinforce each other.
3. Body image, confidence, and mood. Losing 15–20% of body weight changes how people feel in their own bodies and with partners. The patient-reported quality-of-life gains in the SURMOUNT program^[1][2] capture part of this, and improved self-image and mood are well-documented contributors to sexual desire.
4. Resolution of obesity-linked low libido. When low desire was itself a symptom of the metabolic and hormonal burden of obesity — fatigue, sleep apnea, low testosterone, depressed mood — treating the obesity treats the cause. For these patients, libido does not just nudge up; it can recover meaningfully.

Why libido can go DOWN on tirzepatide

The downside is real but usually transient and concentrated in the early, titrating weeks.

• Early nausea, GI upset, and fatigue. Tirzepatide's most common side effects are nausea, diarrhea, constipation, and tiredness, clustered during dose escalation^[1]. Feeling queasy and depleted is not conducive to desire. These symptoms typically fade as the dose stabilizes.
• The catabolic, low-calorie state. Tirzepatide works in large part by sharply reducing appetite and intake. A steep, sustained calorie deficit can transiently lower libido in anyone — the body downshifts non-essential drives, including sex drive, when energy availability drops. Adequate protein and not under-eating help; see our note below.
• Androgen normalization in some women. In women with PCOS, GLP-1 receptor agonists lower the elevated androgens that characterize the condition^[14]. That is metabolically and reproductively beneficial, but because androgens contribute to female desire, some women may notice a libido shift as levels normalize. This is specific to the high-androgen PCOS subgroup, not women generally.
• Rapid weight loss and relationship dynamics. Fast body change can alter self-perception and partnered dynamics in ways that occasionally dampen desire before the body-image benefit takes over. This is psychosocial, not pharmacologic.
• Underlying causes unmasked, not created. Low libido that persists past the adjustment period often reflects a pre-existing issue — untreated low testosterone, thyroid dysfunction, depression, an SSRI or other medication — that warrants its own evaluation rather than being attributed wholesale to tirzepatide.

Men vs women: where the evidence diverges

In men, the story is relatively clean: obesity lowers testosterone, low testosterone lowers libido and erectile function, and weight loss reverses much of that^[7][8][9]. A man who loses 15–20% of body weight on tirzepatide has a reasonable expectation of rising testosterone and improving erectile function over 6–24 months — provided other modifiable factors (sleep apnea, untreated diabetes or hypertension, smoking) are also addressed. For depth on the male side, see our GLP-1 and erectile dysfunction evidence review, the "Ozempic penis" phenomenon, and TRT vs weight loss for low testosterone.

In women, hormonal drivers of desire are more complex and there is less direct data. The favorable signals come from the obesity-and-female-sexual-function literature: obesity and cardiometabolic risk are linked to lower sexual function (Princeton III^[12]; Giugliano 2010^[11]), and weight loss — including the durable improvements seen five years after bariatric surgery^[13] — tends to improve it. The complicating factor is androgens: GLP-1 receptor agonists lower elevated androgens in PCOS^[14], and a broad umbrella review confirms weight-loss interventions shift sex hormones in both sexes^[15]. Because androgens contribute to female desire, the net effect in any individual woman depends on her baseline. The women-specific tirzepatide spoke covers this in full.

How tirzepatide's weight loss compares to interventions with sexual-function data

The chart makes the inference concrete. The Esposito lifestyle program produced about the same percentage weight loss as semaglutide in STEP-1, and that program restored erectile function in roughly a third of obese men over two years. Tirzepatide removes meaningfully more weight than either. If weight loss is the engine of sexual-function improvement — and the evidence says it largely is — then tirzepatide sits at the favorable end of that range for people with obesity. The caveat, repeated honestly: this is a magnitude argument, not a measured sexual-function endpoint.

Practical guidance

• Expect a possible early dip, then recovery. If desire drops in the first few weeks, that usually tracks the nausea and fatigue of dose escalation and tends to improve as you stabilize on a dose.
• Do not under-eat. Tirzepatide suppresses appetite hard. Eating too little for too long deepens the catabolic state that can blunt libido (and costs lean mass). Aim for adequate protein — our GLP-1 protein calculator estimates a 1.6–2.0 g/kg target.
• Pair with resistance training. Preserving lean mass supports testosterone-friendly metabolic health and body composition; see exercise pairing on a GLP-1.
• Men: check testosterone if libido stays low. A morning total testosterone (confirmed on a second draw if low) tells you whether obesity-related hypogonadism is in play. Sustained weight loss is often the first-line fix before considering testosterone therapy — compare the options in TRT vs weight loss.
• Women with PCOS: expect androgen changes. Falling androgens are part of the metabolic benefit, but they can shift desire. Track how you feel and discuss it with your clinician.
• Get a workup for persistent low libido. If desire stays low past the adjustment period, evaluate the usual suspects — thyroid, iron, mood, SSRIs and other medications, sleep apnea — rather than assuming the drug is solely responsible.
• Brand note. Mounjaro and Zepbound are the same molecule (tirzepatide) at the same doses for different on-label uses — see Mounjaro vs Zepbound. Neither has a libido advantage over the other.

What we still don't know

• No tirzepatide RCT has used a validated sexual-function instrument (IIEF, FSFI) as a primary or pre-specified secondary endpoint, so the size and timing of libido change is not directly quantified.
• Whether the dual GIP/GLP-1 mechanism has any weight-independent effect on sexual function — positive or negative — has not been tested. Current evidence shows none.
• The durability of any libido or testosterone benefit after stopping tirzepatide is unstudied. Because weight regain after cessation is documented, it is reasonable to assume sexual-function gains track weight in both directions.
• The female side is especially under-studied. The androgen-lowering effect in PCOS has clear metabolic benefits, but its net effect on desire across different baselines has not been measured in a dedicated trial.

Bottom line

• No randomized trial has measured libido on tirzepatide (Mounjaro, Zepbound). Any confident "it raises it" or "it lowers it" claim outruns the evidence.
• The dominant medium-term direction for people with obesity is UP, driven by weight loss of −15% to −21%^[1][2] — which raises testosterone in men^[7][8][9], improves erectile and female sexual function^[4][12][13], and lifts body image and mood.
• The early weeks can lower sex drive through nausea, fatigue, and the steep calorie deficit. This is usually transient.
• In women with PCOS, GLP-1 receptor agonists lower elevated androgens^[14] — beneficial metabolically, but it can shift desire.
• The GIP component shows no independent libido effect. The honest model is that tirzepatide changes sex drive through weight, hormones, and mood — not by acting on desire directly.
• Persistent low libido warrants a workup (testosterone in men, thyroid, mood, medications), not an automatic assumption that the drug is the sole cause.

Related research and tools

• GLP-1 libido and sex drive: the evidence hub — the both-directions framing across the whole drug class
• Tirzepatide and sex drive in women — the women-specific deep dive, including the PCOS androgen question
• GLP-1s and erectile dysfunction — the verified weight-loss-and-ED evidence base for men
• The "Ozempic penis" phenomenon explained — why weight loss changes erectile function
• TRT vs weight loss for low testosterone — functional hypogonadism is often reversible with weight loss alone
• Mounjaro vs Zepbound: complete comparison — same molecule, different label
• GLP-1 protein calculator — hit a 1.6–2.0 g/kg target to protect lean mass and avoid an over-deep deficit

Important disclaimer. This article is educational and does not constitute medical advice. No randomized controlled trial has measured libido or sexual function as an endpoint for tirzepatide; the relationships described here are inferred from weight-loss and hormonal evidence and are labeled as such. Persistent low libido warrants clinical evaluation — including a morning total testosterone in men, thyroid and iron studies, and a medication and mood review. Do not start, stop, or change any prescription medication based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-06-19.